Abstract: Disclosed is a synthetic peptide, useful as an immunocontraceptive agent and for the diagnosis of autoimmune infertility, which corresponds to an autoantigenic epitope of Rabbit Sperm Membrane Autoantigen (RSA). The synthetic peptide is selected from the group consisting of the decapeptide NH.sub.2 -pro-gly-gly-gly-thr-leu-pro-pro-ser-gly-COOH and the antigenic equivalents thereof.Also disclosed is a method of diagnosing autoimmune infertility in a human subject. The method comprises the step of, first, contacting an immune sera sample from the subject with an antigen, the antigen selected from the group consisting of RSA, other proteins which bind selection antibodies which bind to RSA, and derivatives thereof which bind selection antibodies which bind to RSA. The next step is to detect the presence of antibodies from the immune sera sample bound to the antigen, the presence of antibodies bound to the antigen suggesting the subject is afflicted with autoimmune infertility.
Type:
Grant
Filed:
November 24, 1989
Date of Patent:
December 29, 1992
Assignee:
The University of North Carolina at Chapel Hill
Abstract: A prophylactic agent for controlling venereal diseases. As an active microbicidal component, the agent has an ammonium compound having hydrolyzable ester group.
Type:
Grant
Filed:
June 29, 1988
Date of Patent:
January 14, 1992
Assignee:
Berol Kemi AB
Inventors:
Stig Allenmark, Magnus Lindstedt, Lars Edebo
Abstract: The invention is directed to a composition and a method for preparing the same which composition inhibits or destroys unicellular living organisms. The composition is effective as a spermicide and also in combating sexually transmitted diseases and as an antiseptic agent. The composition of the invention comprises lithium and ionic or ionizable fluorine, for example, lithium fluoride. A suitable excipient such as KATHON may also be present. The invention may, for example, comprise lithium fluoride and a spermicidal agent, such as a quaternary ammonium compound, for example, benzalkonium chloride.
Type:
Grant
Filed:
September 20, 1988
Date of Patent:
November 5, 1991
Assignee:
Atlantic Pharmaceutical Products Ltd.
Inventors:
Pierre Bourbon, Pierre Lagny, Pierre Billot
Abstract: Pharmaceutical compositions comprising a combination of a polymeric biguanide and a spermicidal surfactant, useful for contraceptive purposes, for their spermicidal or sperm-immobilizing effect, and contraceptive methods and devices using them.The polymeric biguanide is preferably a compound as described in U.K. Patent Specification No. 702,268 or a bisbiguanide as described in U.K. Patent Specification No. 705,838 or 1,095,902, but especially chlorhexidine. The spermicidal surfactant may be derived from ethylene oxide, preferably a condensate of nonylphenol and ethylene oxide, and especially with 9 to 11 molecular proportions thereof.To avoid short-lived activity, the compositions are preferably made substantially free from anions (notably halide ions and especially chloride ions) which cause deactivation, apparently by reducing the solubility of the active ingredients.
Abstract: Compositions and methods for providing long lasting contraceptive protection comprising a mixture of a contraceptive effective amount of spermicidal agent, a polymeric gum, a dispersing agent, and a water miscible polyethylene glycol polymer suppository base; and mammalian contraceptive methods utilizing the compositions of the invention in suppository form to provide up to 12 hours of contraceptive protection after initial insertion of the suppository.
Type:
Grant
Filed:
August 16, 1988
Date of Patent:
March 12, 1991
Assignee:
Ortho Pharmaceutical Corporation
Inventors:
Nawaz Ahmad, George A. Ziets, Sudeb Das
Abstract: The inventive composition comprises an active ingredient, for example a quaternary ammonium compound, which active ingredient is capable of inhibiting or destroying a unicellular living organism, such as spermatazoa, bacteria or virus. The active ingredient is combined in a synergistic amount with an activating ingredient capable of inhibiting or destroying the enzymes associated with the unicellular organism. The activating ingredient may be capable of releasing fluoride ions, for example, an inorganic fluoride compound. The composition according to the invention is useful, for example, as a spermicide, or as an antibiotic, or as an anti-STD preparation for local or topical application.
Type:
Grant
Filed:
May 22, 1987
Date of Patent:
April 17, 1990
Assignee:
Atlantic Pharmaceutical Products, Ltd.
Inventors:
Pierre Bourbon, Pierre Lagny, Pierre Billot
Abstract: The in-vivo or in-vitro administration of platelet activating factor (PAF) or analogue enhances the viability of fertilized embryos and improves rates of implantation in the uterus. Conversely, reduction of PAF concentration by in-vivo administration of PAF-antagonists such as Iloprost or PAF antibodies, has a contraceptive effect; particularly when used in conjunction with a post-coital contraceptive such as estrogen or a prostaglandin.
Type:
Grant
Filed:
August 18, 1987
Date of Patent:
November 7, 1989
Assignee:
Royal North Shore Hospital and Area Health Service
Abstract: A transdermal delivery system for the administering of ethinyl estradiol and levonorgestrel, in combination, utilizing a polymer matrix having the drug formulation along with a permeation enhancer dispersed throughout.
Type:
Grant
Filed:
February 26, 1987
Date of Patent:
March 28, 1989
Assignee:
ALZA Corporation
Inventors:
Diane E. Nedberge, Patricia S. Campbell, Robert M. Gale, Su I. Yum
Abstract: A protein having a molecular weight of from about 10,000 to 18,000 daltons, isoelectric points of from about pH 4.0 to 6.5 and having the reversible biological effect of inhibiting aromatase activity in a biological system, and antibodies to the protein, modulate follicular development and spermatogenesis and provide for diagnostic tests of gonadal functions.
Abstract: A male contraceptive preparation is disclosed. The contraceptive preparation consists essentially of 1,2,3-trihydroxypropane in solution in a suitable carrier such as distilled water or saline solution. The method of contraception comprises injecting the contraceptive preparation into the testes. The 1,2,3-trihydroxypropane has been found to act as a potent inhibitor of spermatogenesis, resulting in long term infertility, with no apparent effect on libido, secondary sex characters, mating behaviour and hormone levels. There are no observed side effects and no observed effects on other aspects of reproductive and hormonal biology.
Abstract: Antibody or antigen containing microparticles for the active or passive immunization of the internal female reproductive organs, comprising: microparticles of an antigen or antibody incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.
Type:
Grant
Filed:
January 24, 1986
Date of Patent:
July 12, 1988
Assignee:
Stolle Research & Development Corp.
Inventors:
Lee R. Beck, Charles F. Flowers, Jr., Donald R. Cowsar, Albert C. Tanquary
Abstract: The invention discloses a novel use of Mullerian Inhibiting Substances (MIS) as a contraceptive agent. MIS has been found to inhibit the maturation of oocytes in vitro. Additionally, the invention provides a means for restoring the fertility of females who are infertile due to abnormal production of MIS.
Abstract: A method of prophylactics with respect to deodorization by ascorbic acid, salts and esters, topically applied by means of carriers which are otherwise regularly employed in the vaginal area, such as a pharmacological appliance including gauze pads, an absorbant mass or pad associated with menses, douches, and contraceptive compositions.
Abstract: A method of prophylactics with respect to detoxification of Staphylococcus aureus and other toxins by ascorbic acid, salts and esters, topically applied by means of carriers which are otherwise regularly employed in the area where Staphylococcus aureus or other bacteria colonize, such as a pharmacological appliance including gauze pads, an absorbant mass or pad associated with menses, douches, and contraceptive compositions.
Type:
Grant
Filed:
January 16, 1986
Date of Patent:
February 2, 1988
Inventors:
Joseph Jacob, John R. Lau, W. Blair Geho
Abstract: A male contraceptive preparation and a contraceptive technique are disclosed. The contraceptive preparation consists essentially of 1,2,3-trihydroxypropane ("THP"; glycerol) in solution in a suitable carrier such as distilled water or saline solution. In accordance with the contraceptive technique, the contraceptive preparation is injected into the testes. The THP has been found to act as a potent inhibitor of spermatogenesis, resulting in long term infertility, with no apparent effect on libido, secondary sex characters, mating behavior and hormone levels. There are no observed side effects and no observed effects on other aspects of reproductive and hormonal biology.
Abstract: Fused tetracyclic benzodiazepines of the formula (I): ##STR1## where R.sup.1 is a cyclic amine such as 1-piperazine and R.sup.2 is H or a substituent as defined herein are useful as LHRH antagonizing agents. Also, methods for their synthesis, intermediates used in such synthesis, methods for use as medicaments and pharmaceutical compositions are described.
Abstract: A method for reducing the time to estrus onset and duration of estrus in female bovines, is described. The method involves a sustained low level release of progestin over time with injection of a luteolytic agent, particularly a prostaglandin, towards the end of the time such that there is an overlap of progestin and prostaglandin administration. The sustained release is preferably by means of a vaginal implant. The method is faster and easier to use than prior art methods.
Type:
Grant
Filed:
August 6, 1984
Date of Patent:
September 9, 1986
Assignee:
Board of Trustees Operating Michigan State University
Abstract: This disclosure relates to the aspermatogenesis activity of(a) compounds of the formula: ##STR1## where m is an integer from 1 to 4X represents hydrogen or --OHR represents Ar, ##STR2## Ar represents ##STR3## R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl or lower alkoxy, R.sub.2 and R.sub.3 each, independently, represent lower alkyl, orR.sub.2 and R.sub.3 together with N represent ##STR4## wherein n is 1, 2 or 3,R.sub.4 represents hydrogen or lower alkyl, andR.sub.5 represents hydrogen or lower alkyl, unsubstituted phenyl or phenyl mono- or di-substituted with fluoro, chloro, lower alkyl or lower alkoxy, or(b) compounds of the formula: ##STR5## where R' is Ar or ##STR6## Ar, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined above, or a pharmaceutically acceptable acid addition salt thereof.
Abstract: A compound useful as antifungal, antibacterial and antiprotozoal agents and as spermicides have the formula ##STR1## and the acid addition salts thereof wherein Z is oxygen or sulfur;m is 0, 1, 2 or 3;n is 1, 2 or 3;R.sup.1 is hydrogen; alkyl; cycloalkyl; cycloalkyl-lower-alkyl; optionally substituted phenyl; phenyl-lower-alkyl; monocyclic heteroaromatic ring; monocyclic heteroaromatic-lower-alkyl; naphthyl; or naphthyl-lower-alkyl.A and B are independently hydrogen, halo, lower alkyl or lower alkoxy and either one of A or B may be nitro, amino or alkanoylamino;Q is (a) NR.sup.2 R.sup.3 or (b) NR.sup.4 C(X)YR.sup.5 whereinX is oxygen or sulfur;Y is oxygen, sulfur, NR.sup.6 or a bond;R.sup.2 is hydrogen; alkyl; cycloalkyl; cycloalkyl-lower-alkyl; optionally substituted phenyl or optionally substituted phenyl-lower-alkyl;R.sup.3 is hydrogen or lower alkyl; orR.sup.2 and R.sup.3 together with N is a five or six membered optionally substituted ring;R.sup.4 and R.sup.6 are independently hydrogen or lower alkyl;R.